MBX Biosciences, Inc. Common Stock
MBX Biosciences, Inc. Common Stock
Your view on MBX
Overview
What the company does, where it operates, and who runs it.
About MBX Biosciences, Inc. Common Stock
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Peter Kent Hawryluk
- Headquarters
- US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Peter Kent Hawryluk
- Headquarters
- US
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders.
Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.
The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery.
In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities.
The company was founded in 2018 and is based in Carmel, Indiana.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for MBX Biosciences, Inc. Common Stock, and the rating behind it. MBX last traded at $59.02; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for MBX Biosciences, Inc. Common Stock. Starting points for MBX Biosciences, Inc. Common Stock: EPS -$2.19, beta 0.10 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for MBX Biosciences, Inc. Common Stock. MBX Biosciences, Inc. Common Stock does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for MBX Biosciences, Inc. Common Stock. Trailing twelve-month EPS for MBX Biosciences, Inc. Common Stock stands at -$2.19. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for MBX Biosciences, Inc. Common Stock. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
MBX Biosciences, Inc. Common Stock valued side by side against its closest peers. MBX Biosciences, Inc. Common Stock is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold MBX Biosciences, Inc. Common Stock, and how their positions are changing. At a $2.81B market value, institutional positions materially move MBX Biosciences, Inc. Common Stock's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by MBX Biosciences, Inc. Common Stock executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming MBX Biosciences, Inc. Common Stock. MBX Biosciences, Inc. Common Stock is a $2.81B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming MBX Biosciences, Inc. Common Stock. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for MBX Biosciences, Inc. Common Stock. Coverage tracks MBX Biosciences, Inc. Common Stock within Biotechnology (Healthcare). Press releases and market coverage, newest first.